At Xcellon Biologics, our mission is to be the global leader in delivering innovative, flexible, and scalable solutions for biologics manufacturing. We empower our partners to advance life-saving therapies with unparalleled efficiency, quality, and reliability.

Who We Are

Xcellon Biologics is a highly specialized CDMO focused on complex biologics including Antibody Drug Conjugates (ADCs), Bioconjugates, Bispecific Antibodies, and T-Cell Engagers.

Our expertise spans lead candidate selection through process development and manufacturing—helping biopharmaceutical companies overcome technological hurdles and accelerate the path from discovery to market.

With a team of industry-leading scientists, advisors, and biotech entrepreneurs, we bring decades of experience in biologics development, bioconjugation, and GMP manufacturing.

We Specialize In:

Why Choose Xcellon?

Decades of Industry Expertise:

Our team has collectively launched over 30 products, filed 20+ INDs, and has 40+ years of experience in both biologics and bioconjugates.

Strategic Location:

Based in Maryland, we are near key regulatory and research institutions like the FDA, NIH, and USP, ensuring compliance and cutting-edge advancements.

Cutting-Edge Facilities:

7,000+ sq ft operational lab space in Rockville, MD.

Machine Learning Innovation:

We integrate machine learning (ML) to improve process efficiency, reduce development timelines, and enhance manufacturing predictability.

Our leadership comprises renowned scientists and industry veterans.

Yuk Chun Chiu, MEng

Co-Founder & Chief Operating Officer

Jared Mattos, PhD

Principal Scientist

Jeffrey Lopez, PhD

Principal Scientist

Kevin Gray, PhD

Principal Scientist

Morris Rosenberg, PhD

Senior Advisor

Sanjeevani Ghone, PhD, MBA

Senior Advisor

Abhishake Chhibber

Co-Founder & Board Member

Thomas Haag

Co-Founder & Board Member

Partner
With Us

Partner With Us

Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.

We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.